Leonid Beigelman's most recent trade in Aligos Therapeutics Inc was a trade of 169,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 15, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aligos Therapeutics Inc | Leonid Beigelman | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 169,500 | 169,500 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Leonid Beigelman | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 113,000 | 113,000 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Leonid Beigelman | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 226,800 | 226,800 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Leonid Beigelman | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 56,700 | 56,700 | - | - | Stock Option (Right to Buy) |